Lialda: adverse event reports filed with FDA

3,749

reports as suspect product

0% of all reports · about 195 a year

165

reports, 12 months to June 2026

277 in the 12 months before

56.4%

marked serious by the reporter

86.5% across the class

1.8%

record death among outcomes, as reported

66 reports · not verified by FDA

Reports by month, five years

Reports by the month FDA received them. FDA releases FAERS data quarterly, so the newest months are incomplete and grow in later releases.

By year received

2026 covers reports received through June 2026 only.

Reactions recorded in the reports

share of Lialda reports recording the termmedian drug in aminosalicylate

1. Drug ineffectivethe medicine did not work as expected14%523
2. Colitis ulcerative10%376
3. Diarrhoealoose or frequent stools9.9%372
4. Haematocheziablood in the stool9.6%361
5. Condition aggravatedthe condition being treated got worse6.1%229
6. Inappropriate schedule of drug administrationthe medicine was taken at the wrong times5.6%209
7. Product use issuea problem in how the product was used5.4%203
8. Abdominal painstomach or belly pain5.3%198
9. No adverse eventno adverse event was reported5.3%198
10. Off label useused for a purpose or in a way not on the label4.2%156
11. Pyrexiafever3.7%140
12. Headachehead pain3.5%130
13. Frequent bowel movements3.4%128
14. Arthralgiajoint pain3.4%127
15. Nauseafeeling sick3.3%124
16. Medication residue present3.2%121
17. Alopeciahair loss3.1%117
18. Malaisegeneral feeling of being unwell2.8%106
19. Painpain, site not specified2.7%101
20. Fatiguetiredness2.6%96
21. Haemorrhagebleeding2.5%94
22. Pancreatitisinflammation of the pancreas2.4%91
23. Rashskin rash2.3%88
24. Dizzinesslight-headedness or unsteadiness2.2%84
25. Weight decreasedweight loss2.2%84
26. Product quality issuea problem with the product itself2.2%83
27. Drug dose omissiona dose was missed2.2%81
28. Drug intolerancethe medicine was not tolerated2.1%80
29. Inability to afford medication2.1%80
30. Astheniaweakness or lack of energy2.1%78

Top 30 of 447 MedDRA preferred terms recorded across these reports, with a plain-language gloss where one is available. One report can record several terms. The hollow bar is the median share across the 7 drugs in the aminosalicylate class; it describes the reports, not the patients. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Outcomes recorded

Outcome flags as the reporter set them; a report can carry several, and "other serious" is FDA's own category for serious reports outside the named outcomes. Grey bar: all 59,220 reports in the class. FDA has not verified any outcome and states that the reports "cannot be used to estimate the incidence of these events."

Patients and reporters

Age and sex as stated in the report; the reporter's qualification is the primary source recorded by FDA. 74.6% of reports give the United States as the country of the event or reporter.

Reason for use recorded

The indication field is filled in by the reporter and is often blank; shares are of all 3,749 reports.

Drugs most often listed in the same reports

Other products listed in reports where Lialda is a suspect product, whatever their own role. Co-listing means the two were recorded together; it says nothing about either product's part in the event. Only the 2,500 most-reported names are counted here.

In context

Shares are of reports, not of patients treated. The number of people taking a product is not in the data, so none of these figures is a rate, and differences between columns reflect who takes a product, who reports and how long it has been sold. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic."

Other drugs in the aminosalicylate class

Ordered by report count for navigation only. FDA states that adverse event reports "represent a small percentage of total usage numbers of a product", that "common products may have a higher number of adverse events due to the higher total number of people using the product", and that the data "by themselves are not an indicator of the safety profile of the drug or biologic." A brand and its generic are separate rows because reporters name them separately.

Where this comes from. Counts are built from the openFDA Drug Adverse Event (FAERS) bulk export released 28 Sep 2026, which holds reports FDA received through 30 Jun 2026. Drug names are as reported, resolved to the brand or generic name on the FDA label where openFDA's harmonisation matched them; classes are the pharmacologic class (EPC) from the label and the National Drug Code Directory of 17 Sep 2026. A report counts here when it lists Lialda as a suspect or interacting product; reports listing it only as a concomitant medication (5,560) are excluded. No report narrative, lot number, patient detail or reporter identity is published. See the methodology and sources; FDA's record is authoritative, and corrections are handled within five working days.